Impaired thymic output in patients with chronic hepatitis c virus infection

Scandinavian Journal of Immunology

Volumn 78, Issue 4, 2013, Pages 378-386

  Hartling, H J ^a   Gaardbo, J C ^a   Ronit, A ^a   Salem, M ^a   Laye, M ^a   Clausen, M R ^a   Skogstrand, K ^b   Gerstoft, J ^a   Ullum, H ^a   Nielsen, S D ^a  

^a Rigshospitalet   (Denmark)

^b STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 7 RECEPTOR;

ADULT; ARTICLE; BLOOD ANALYSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CROSS-SECTIONAL STUDY; FEMALE; FLOW CYTOMETRY; HEPATITIS C; HOMEOSTASIS; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; T LYMPHOCYTE; TELOMERE;

ADULT; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CROSS-SECTIONAL STUDIES; FEMALE; FIBROSIS; FLOW CYTOMETRY; HEPACIVIRUS; HEPATITIS C, CHRONIC; HOST-PATHOGEN INTERACTIONS; HUMANS; INTERLEUKIN-7 RECEPTOR ALPHA SUBUNIT; LIVER; MALE; MIDDLE AGED; TELOMERE; THYMUS GLAND;

EID: 84883829529     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12096     Document Type: Article

References (52)

1. Freeman AJ, Dore GJ, Law MG et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001;34:809-16.
2. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-32.
3. Neuman MG, Sha K, Esguerra R et al. Inflammation and repair in viral hepatitis C. Dig Dis Sci 2008;53:1468-87.
4. Benhamou Y, Bochet M, Di Martino V et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999;30:1054-8.
5. Martín-Carbonero L, Benhamou Y, Puoti M et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis 2004;38:128-33.
6. Casrouge A, Decalf J, Ahloulay M et al. Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J Clin Investig 2011;121:308.
7. Caetano J, Martinho A, Paiva A, Pais B, Valente C, Luxo C. Differences in hepatitis C virus (HCV)-specific CD8 T-cell phenotype during pegylated alpha interferon and ribavirin treatment are related to response to antiviral therapy in patients chronically infected with HCV. J Virol 2008;82:7567-77.
8. Opravil M, Sasadeusz J, Cooper DA et al. Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection. J Acquir Immune Defic Syndr 2008;47:36-49.
9. Pilli M, Zerbini A, Penna A et al. HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project). Gastroenterology 2007;133:1132-43.
10. + T-cell responses. J Viral Hepatitis 2007;14:318-29.
11. Lee S, Hammond T, Watson MW et al. Could a loss of memory T cells limit responses to hepatitis C virus (HCV) antigens in blood leucocytes from patients chronically infected with HCV before and during pegylated interferon-alpha and ribavirin therapy? Clin Exp Immunol 2010;161:118-26.
12. Neau-Cransac M, Foucher J, De Ledinghen V, Bernard P-H, Legrand E, Lafon M-E. Modifications of T-lymphocyte subsets before and during interferon and ribavirin treatment for chronic hepatitis C infection. Viral Immunol 2005;18:197-204.
13. Shire NJ, Welge JA, Sherman KE. Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: a research synthesis. J Viral Hepatitis 2007;14:239-48.
14. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
15. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36:S237-44.
16. + T cell responses in hepatitis C virus infection. World J Gastroenterol 2007;13:4831-8.
17. Klenerman P, Thimme R. T cell responses in hepatitis C: the good, the bad and the unconventional. Gut 2012;61:1226-34.
18. + T-cell subsets. Blood 2009;113:769-74.
19. Kimmig S, Przybylski GK, Schmidt CA et al. Two subsets of naive T helper cells with distinct T cell receptor excision circle content in human adult peripheral blood. J Exp Med 2002;195:789-94.
20. Li J, Huston G, Swain SL. IL-7 promotes the transition of CD4 effectors to persistent memory cells. J Exp Med 2003;198:1807-15.
21. Kondrack RM, Harbertson J, Tan JT, McBreen ME, Surh CD, Bradley LM. Interleukin 7 regulates the survival and generation of memory CD4 cells. J Exp Med 2003;198:1797-806.
22. Kaech SM, Tan JT, Wherry EJ, Konieczny BT, Surh CD, Ahmed R. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol 2003;4:1191-8.
23. Fyhrquist F, Saijonmaa O. Telomere length and cardiovascular aging. Ann Med 2012;44 (Suppl. 1):S138-42.
24. +, subpopulations in hepatitis C virus (HCV)-HIV-co-infected patients during treatment with interferon alpha plus ribavirin: analysis in a population on effective antiretro. Clin Exp Immunol 2006;146:270-7.
25. Massanella M, Tural C, Papagno L et al. Changes in T-cell subsets in HIV-HCV-coinfected patients during pegylated interferon-alpha2a plus ribavirin treatment. Antivir Ther 2010;15:333-42.
26. Roe B, Coughlan S, Dean J et al. Phenotypic characterization of lymphocytes in HCV/HIV co-infected patients. Viral Immunol 2009;22:39-48.
27. Chattopadhyay PK, Roederer M. Good cell, bad cell: flow cytometry reveals T-cell subsets important in HIV disease. Cytometry 2010;77:614-22.
28. Yonkers NL, Sieg S, Rodriguez B, Anthony DD. Reduced naive CD4 T cell numbers and impaired induction of CD27 in response to T cell receptor stimulation reflect a state of immune activation in chronic hepatitis C virus infection. J Infect Dis 2011;203:635-45.
29. Cianci R, Pinti M, Nasi M et al. Impairment of recent thymic emigrants in HCV infection. Int J Immunopathol Pharmacol 2005;18:723-8.
30. + T cell subsets in chronic HCV infection. Arch Virol 2010;155:627-34.
31. Beq S, Rozlan S, Pelletier S et al. Altered thymic function during interferon therapy in HCV-infected patients. PLoS One 2012;7:e34326.
32. + T-cells or gammadelta T-cells, in HIV patients responding to ART. Immunol Cell Biol 2010;88:321-7.
33. Hartling HJ, Gaardbo JC, Ronit A et al. CD4(+) and CD8(+) regulatory T cells (Tregs) are elevated and display an active phenotype in patients with chronic HCV mono-infection and HIV/HCV co-infection. Scand J Immunol 2012;76:294-305.
34. Ronit A, Salem M, Hartling HJ et al. Dysregulation of toll-like receptor (TLR) 2 expression on monocytes and upregulation of the frequency of T cells expressing TLR2 in patients with chronic hepatitis C virus infection. APMIS 2013;121:437-46.
35. Skogstrand K, Thorsen P, Nørgaard-Pedersen B, Schendel DE, Sørensen LC, Hougaard DM. Simultaneous measurement of 25 inflammatory markers and neurotrophins in neonatal dried blood spots by immunoassay with xMAP technology. Clin Chem 2005;51:1854-66.
36. Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res 2002;30:e47.
37. Gaardbo JC, Hartling HJ, Gerstoft J, Nielsen SD. Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions. Clin Dev Immunol 2012;2012:670957.
38. Hunt PW. HIV and inflammation: mechanisms and consequences. Curr HIV/AIDS Rep 2012;9:139-47.
39. Kolte L, Dreves A-M, Ersbøll AK et al. Association between larger thymic size and higher thymic output in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. J Infect Dis 2002;185:1578-85.
40. Li T, Wu N, Dai Y et al. Reduced thymic output is a major mechanism of immune reconstitution failure in HIV-infected patients after long-term antiretroviral therapy. Clin Infect Dis 2011;53:944-51.
41. Appay V, Van Lier RAW, Sallusto F, Roederer M. Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry 2008;73:975-83.
42. Rethi B, Fluur C, Atlas A et al. Loss of IL-7Ralpha is associated with CD4 T-cell depletion, high interleukin-7 levels and CD28 down-regulation in HIV infected patients. AIDS 2005;19:2077-86.
43. Sawa Y, Arima Y, Ogura H et al. Hepatic interleukin-7 expression regulates T cell responses. Immunity 2009;30:447-57.
44. Golden-Mason L, Burton JR, Castelblanco N et al. Loss of IL-7 receptor alpha-chain (CD127) expression in acute HCV infection associated with viral persistence. Hepatology 2006;44:1098-109.
45. Soriano-Sarabia N, Vallejo A, Molina-Pinelo S et al. HIV-hepatitis C virus co-infection is associated with decreased plasmatic IL-7 levels. AIDS 2007;21:253-5.
46. Romeo R, Colombo M, Rumi M et al. Lack of association between type of hepatitis C virus, serum load and severity of liver disease. J Viral Hepatitis 1996;3:183-90.
47. Puoti C, Stati T. Magrini a. Serum HCV RNA titer does not predict the severity of liver damage in HCV carriers with normal aminotransferase levels. Liver 1999;19:104-9.
48. Ferreira-Gonzalez A, Shiffman ML. Use of diagnostic testing for managing hepatitis C virus infection. Semin Liver Dis 2004;24 (Suppl. 2):9-18.
49. Everson GT, Hoefs JC, Seeff LB et al. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial. Hepatology 2006;44:1675-84.
50. Bader el-Din NG, Abd el-Meguid M, Tabll AA et al. Human cytomegalovirus infection inhibits response of chronic hepatitis-C-virus-infected patients to interferon-based therapy. J Gastroenterol Hepatol 2011;26:55-62.
51. Tabll A, Shoman S, Ghanem H, Nabil M, El Din NGB, El Awady MK. Assessment of human cytomegalovirus co-infection in Egyptian chronic HCV patients. Virol J 2011;8:343.
52. skarieh G, Alsiö A, Pugnale P et al. Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology 2010;51:1523-30.